[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Lab Reports
November 3, 2010

Cardiovascular Risk from Coxibs

JAMA. 2010;304(17):1888. doi:10.1001/jama.2010.1520

Cardiovascular events resulting from long-term, high-dosage use of selective cyclooxygenase 2 (COX-2) inhibitors, or coxibs, are linked to a surge in blood levels of a metabolite that is a potent vasoconstrictor and that increases platelet aggregation and clot formation, reported scientists at the University of California, Davis, and Beijing University in China (Liu J-Y et al. Proc Natl Acad Sci U S A. doi:10.1073/pnas.1011278107 [published online September 13, 2010]).

First Page Preview View Large
First page PDF preview
First page PDF preview